In an interview to CNBC-TV18's Ekta Batra and Vikas Dandekar, the Executive Chairman of Torrent Pharma, Samir Mehta spoke about the rationale behind the deal and where it would take the company in the Indian pharmaceutical market.

Aim is to prevent rampant use of antibiotics: P Lilladher

Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.

Godrej Prop sells its BKC project for Rs 1,479cr to Abbott

The project was being developed for Jet Airways on a 50:50 profit-sharing agreement.

'India to lead global growth; bet on financial services'

Ajay Piramal says that Indian growth will be higher than the rest of the world soon and adds that the financial services sector is ripe for investment with lucrative returns on offer.

What is Lupin's acquisition agenda for the future?

Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.